靶向蛋白質分解 (TPD) 治療的新興前景

快速的技術進步加強了強大的處理管道

Frost & Sullivan 的研究報告對新興的靶向蛋白質分解 (TPD) 領域進行了深入分析。透過以受控方式攻擊致病蛋白並降低副作用風險，TPD 策略使得治療多種常規方法仍無法治療的疾病成為可能。

據估計，80%的細胞蛋白質組無法透過小分子抑製劑、ASO 和單克隆抗體等傳統方法來靶向，導致了 TPD 方法的發展。事實上，TPD 在過去二十年中已經取得了長足的進步，PROTAC 已成為有史以來研究的最常見的蛋白水解酶。隨著新技術的出現，已經開發了幾種類型的蛋白水解劑。

主要有兩種類型：細胞內分解劑和細胞外分解劑。迄今為止，細胞內蛋白水解劑已得到最廣泛的研究。他們利用泛素蛋白酶體分解途徑來分解細胞內蛋白質，但估計有 40%的編碼細胞外和膜相關蛋白的基因不能被細胞內蛋白水解劑靶向，這導致了細胞外蛋白水解劑的開發。

增加私人和公共資金是推動靶向蛋白質分解技術發展的關鍵因素。本報告包括對 TPD 行業融資趨勢的分析。

本報告討論了細胞外和細胞內蛋白水解劑的類型及其研發重點領域。還分析了不同分解物在不同疾病中的適用性，並確定其臨床應用和相關關鍵參與者。最後，Frost & Sullivan 為 TPD 確定了四個可以改變市場的成長機會。

本報告試圖回答的問題是：

• 1.TPD發展的主要促進因素和挑戰是什麼？
• 2.TPD 的私人資金和合作夥伴關係狀況如何？
• 3.開發靶向蛋白酶的主要行業相關人員有哪些？
• 4.TPD的研發趨勢有哪些可能促進蛋白水解酶的開發？

目錄

戰略問題

• 為什麼成長如此困難？
• The Strategic Imperative 8 (TM)
• 靶向蛋白水解行業的戰略問題：三大影響
• 透過成長機會加速成長管道引擎 (TM)
• 調查方法
• 介紹

成長機會分析

• 成長促進因素
• 促進因素分析
• 生長抑制因素
• 生長抑制因素分析
• 分析範圍
• 區隔
• 靶向蛋白水解劑需求

研發與創新生態系統

• TPD 的演變和臨床方面
• 細胞內靶向蛋白水解藥物的臨床開發
• 細胞內靶向蛋白水解劑：PROTAC
• 新型細胞內靶向蛋白水解藥物
• 創新焦點：細胞內蛋白質分解
• 細胞外蛋白水解藥物的開發
• 細胞外蛋白水解治療劑開發中的問題
• 細胞外蛋白水解方法
• 細胞外蛋白水解劑的新型
• 創新焦點：細胞外蛋白質分解
• 細胞外和細胞內蛋白質靶標之間的主要區別
• 靶向蛋白水解：技術概覽

研發重點及應用前景

• 研發與創新趨勢
• 醫學及其他領域的蛋白質分解
• 各種疾病領域的蛋白水解劑
• 各大公司及熱點治療領域
• 蛋白水解劑的創新前景

市場動態

• TPD 藥物開發的公共和私人資金
• 生物製藥公司在TPD藥物開發中的合作狀況
• TPD 公司合作開發 TPD 療法

成長機會宇宙

• 成長機會1：分解物的高效和組織特異性遞送
• 成長機會2：新型E3連接酶的發現和設計
• 成長機會3：先進PROTAC的開發
• 成長機會4：研發合作開發下一代TPD藥物

附錄

• 附錄
• 附錄

下一步

• 下一步
• 為什麼選擇 Frost & Sullivan，為什麼現在
• 免責聲明

Rapid Technology Advances Bolster a Robust Therapeutic Pipeline

This Frost & Sullivan research report provides an in-depth analysis of the emerging targeted protein degradation (TPD) space. TPD strategies enable treating various diseases not yet treatable via conventional approaches by attacking disease-causing proteins in a controlled manner, thus reducing the risk of side effects.

It is estimated that 80% of a cell's proteome cannot be targeted via traditional approaches such as small molecule inhibitors, ASO, or monoclonal antibodies, which has led to the development of TPD approaches. Indeed, TPD has advanced enormously in the last two decades, and PROTACs have emerged as the most common protein degrader researched until now. As new technologies emerge, several types of protein degraders have been developed.

Two main types exist: intracellular and extracellular degraders. Until now, intracellular protein degraders have been the most extensively studied. These degrade intracellular proteins by leveraging the ubiquitin-proteasomal degradation pathway, but an estimated 40% of genes encoding extracellular and membrane-associated proteins cannot be targeted by intracellular protein degraders, leading to the development of extracellular protein degradation.

Increased private and public funding is an important factor driving the growth of targeted protein degradation technology. This report includes an analysis of funding trends in the TPD space.

This report discusses the different types of extracellular and intracellular protein degraders and R&D focus areas; it analyses the applicability of different degraders across various diseases and identifies their clinical translation and related key players. Finally, Frost & Sullivan has identified four growth opportunities for TPD that could potentially transform the market.

Questions that this report seeks to answer include:

• 1. What are the key drivers or challenges for TPD development?

• 2. How do the private funding and partnership landscapes look for TPD?

• 3. Who are the key industry participants developing targeted protein degraders?

• 4. What are the R&D trends emerging across TPD that could further shape the development of protein degraders?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Targeted Protein Degradation Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology
• Introduction

Growth Opportunity Analysis

• Growth Drivers
• Growth Driver Analysis
• Growth Restraints
• Growth Restraints Analysis
• Scope of Analysis
• Segmentation
• The Need for Targeted Protein Degraders

R&D and Innovation Ecosystem

• TPD-Evolution and Clinical aspect
• Intracellular Targeted Protein Degraders in Clinical Development
• Intracellular Targeted Protein Degraders-PROTACs
• Emerging Intracellular Targeted Protein Degraders
• Innovation Spotlight-Intracellular Protein Degradation
• Development of Extracellular Protein Degradation Therapeutics
• Challenges for Extracellular Protein Degrader Development
• Extracellular Protein Degradation Approaches
• Emerging Classes of Extracellular Protein Degraders
• Innovation Spotlight-Extracellular Protein Degradation
• Key Differences Between Extracellular and Intracellular Protein Targeting
• Targeted Protein Degradation Technology Snapshot

R&D Focus and Application Landscape

• R&D Innovation Trends
• Protein Degraders in Healthcare and Beyond
• Protein Degraders across Different Disease Areas
• Key Players and Therapeutics Areas of Focus
• Protein Degraders Innovation Landscape

Market Dynamics

• Public and Private Funding for TPD Therapy Development
• Partnership Landscape of Biopharma Companies in TPD Therapeutics Development
• TPD Companies' Partnerships for Developing TPD Therapeutics

Growth Opportunity Universe

• Growth Opportunity 1: Efficient and Tissue-specific Degrader Delivery
• Growth Opportunity 2: Novel E3 Ligases Discovery and Design
• Growth Opportunity 3: Advanced PROTACs Development
• Growth Opportunity 4: Research and Product Development Partnerships to Develop Next-gen TPD Therapeutics

Appendix

• Appendix
• Appendix

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer